A randomised controlled trial of NMDA antagonist, memantine, for the treatment of borderline personality disorder [ 2017 - 2019 ]

Research Grant

Researchers: Prof Jayashri Kulkarni (Principal investigator) ,  Prof Magdalena Plebanski

Brief description Borderline Personality Disorder (BPD) affects 5.9% of Australians and is a poorly understood mental illness with no clear medication treatment. The key symptoms of BPD all stem from impaired cognitive processes. Our early data shows improvement of symptoms with memantine - a cognitive enhancing drug used in Alzheimer’s disease.We plan to conduct a clinical trial; giving either 20mg memantine or placebo to 150 people with BPD across 2 Victorian sites.

Funding Amount $AUD 1,016,344.97

Funding Scheme Project Grants

Notes Standard Project Grant